Interaction Color Code
Clinical Bottom Line
Adjust dosing to avoid reduced levels of dolutegravir
Drug 1
Drug 1 dose
50 mg BID
Drug 1 effect
Cmax decreased 43%, AUC decreased 54%, Cmin decreased 72% (when compared to dolutegravir 50 mg BID without rifampin)
Drug 2
Drug 2 dose
600 mg daily
Drug 2 effect
Not studied
Clinical Effects
Potential decrease in antiretroviral efficacy
Management
Adjust dose of dolutegravir to 50 mg twice daily for treatment-na•ve and treatment experienced, INSTI na•ve adult patients, in pediatrics, increased the weight-based dose to twice daily, Use alternate combinations in INSTI experienced or INSTI resistance patients
Alternative Agents
Rifabutin
Import ID
87
